U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they are unlikely to work against the omicron variant.
Omicron’s resistance to the two leading monoclonal antibody medicines has upended the treatment playbook for COVID-19 in recent weeks.
The U.S. government temporarily stopped distributing the two drugs in late December, as omicron was racing across the country to become the dominant variant. But officials resumed distribution after complaints from Republican governors, including Florida’s Ron DeSantis, who claimed that the drugs continued to help some omicron patients.
The drugs are not a substitute for vaccination and are generally reserved for people who are the most vulnerable, including seniors, transplant recipients and those with conditions like heart disease and diabetes. The move comes days after regulators broadened the use of remdesivir — the first drug approved for COVID-19 — to treat more patients.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Beijing 2022 organisers ease COVID-19 curbs for Games-related personnelOrganisers of the Beijing 2022 Winter Olympics have slightly relaxed their famously strict COVID-19 measures for participants in next month's Games, the International Olympic Committee (IOC) said on Monday.
続きを読む »
Fauci: Omicron COVID-19 infections likely to peak in FebruaryDr. Anthony Fauci said he was 'as confident as you can be' that states will hit their highest point of infections in February
続きを読む »
COVID-19 live updates: New Zealand imposes restrictions amid omicron outbreakNew Zealand Prime Minister Jacinda Ardern revealed that her own wedding will be postponed as she announced a new set of COVID-19 restrictions amid the country’s first omicron outbreak.
続きを読む »